Entrepreneurial training programmes
We help the next generation of scientific entrepreneurs bridge the gap to translate their research. Find out how we can support you.
Nominations close at 5pm on 10 January 2024 and can be submitted for multiple categories via self-nomination or by someone else. Nominations do not need to be funded by Cancer Research UK but must be based in the UK. All nominations will be reviewed by a judging panel of independent experts, which will be announced in the future. Award winners will receive funding, sector-wide recognition, and the chance to inspire the next generation of academic entrepreneurs.
All shortlisted nominees will be invited to attend the awards ceremony at the Law Society on 20 March 2024, where the winners will be announced. For team nominations, up to three representatives will be invited. This black-tie event includes a drinks reception and gala dinner, providing a unique opportunity to network with a range of rising stars, seasoned entrepreneurs, industry experts, and inspiring keynotes.
The following five awards are open for nominations:
- Early Career Entrepreneur of the Year (nominate here)
- Entrepreneurial Group Leader of the Year (nominate here)
- Woman Entrepreneur of the Year (nominate here)
- New Startup of the Year (nominate here)
- Further, Faster, Together (Industry–Academia Collaboration) (nominate here)
There will also be three special awards to recognise outstanding contributions to the academic cancer entrepreneurial field, which are not open to nominations; instead, the judging panel will select winners from shortlists identified by Cancer Research Horizons.
ENDS
About Cancer Research Horizons
Cancer Research Horizons is the innovation engine of Cancer Research UK – the world's largest charitable funder of cancer research. We bring together world-leading minds, bold ideas and the right partners to bridge the gap between academic research and taking drugs to market. We focus on the tougher, more profound ideas that can lead to true innovation, translating them into effective treatments and diagnostics for cancer patients.
To date, we've played an instrumental role in forming over 60 spin-out companies. We've helped bring 11 cancer drugs to market, borne out of Cancer Research UK's pioneering research. Through these drugs, we have enabled in excess of 6 million courses of treatment for cancer patients across the world.
With access to Cancer Research UK's network of 4,000 exceptional researchers, and £300+ million of annual research spend, we're a powerful partner in the fight to conquer cancer. By uniting our commercial partnerships and therapeutic innovation capabilities, Cancer Research Horizons is uniquely placed to support translational funding, entrepreneurial development, licensing and collaboration, spinout creation, and offer a full spectrum of drug discovery and clinical capabilities.
Every penny we make goes back into funding the next bold steps, to help bring forward the day when all cancers are conquered.
For more information and to get in touch with the team, visit cancerresearchhorizons.com
Contact
Tim Bodicoat
Press Officer
Cancer Research Horizons
[email protected]
